About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.410 -0.050 (-3.42%)
Streaming Delayed Price Updated: 9:44 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
From Ocugen
Via GlobeNewswire
News headline image
Navigating 4 Analyst Ratings For Ocugen ↗
 
Via Benzinga
News headline image
A Preview Of Ocugen's Earnings ↗
 
Via Benzinga
News headline image
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
From Ocugen
Via GlobeNewswire
News headline image
Peering Into Ocugen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Shankar Musunuri, CEO of Ocugen Inc. (NASDAQ: OCGN), to Present at NobleCon20
Via Investor Brand Network
News headline image
Ocugen (OCGN) Q3 2024 Earnings Call Transcript ↗
OCGN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET 
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Secures $30 Million in Debt Funding
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
From Ocugen
Via GlobeNewswire
News headline image
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
News headline image
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Q2 2024 Earnings Call Transcript ↗
OCGN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.